DexCom (NASDAQ:DXCM) Price Target Raised to $145.00

DexCom (NASDAQ:DXCM) had its target price lifted by Canaccord Genuity Group from $144.00 to $145.00 in a research report released on Friday morning, Benzinga reports. The firm currently has a buy rating on the medical device company’s stock.

Other equities analysts have also recently issued research reports about the stock. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an outperform rating and a $165.00 price objective on the stock. StockNews.com lowered DexCom from a buy rating to a hold rating in a research report on Tuesday, April 23rd. Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the company a buy rating in a report on Wednesday, April 3rd. UBS Group lifted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a buy rating in a report on Wednesday, April 10th. Finally, Raymond James upped their price objective on shares of DexCom from $147.00 to $151.00 and gave the stock a strong-buy rating in a report on Tuesday, January 23rd. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus target price of $141.67.

DexCom Price Performance

Shares of DexCom stock opened at $125.81 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom has a 52-week low of $74.75 and a 52-week high of $142.00. The company has a fifty day moving average of $131.30 and a 200-day moving average of $119.17. The stock has a market capitalization of $50.03 billion, a price-to-earnings ratio of 81.17, a price-to-earnings-growth ratio of 2.11 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Equities research analysts expect that DexCom will post 1.78 EPS for the current year.

Insider Activity

In related news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the sale, the executive vice president now directly owns 80,441 shares in the company, valued at approximately $10,747,722.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 20,321 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the sale, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock worth $25,530,859 over the last 90 days. 0.41% of the stock is currently owned by insiders.

Institutional Trading of DexCom

Several hedge funds have recently bought and sold shares of the stock. DSM Capital Partners LLC purchased a new stake in DexCom in the 4th quarter worth approximately $28,000. Valley National Advisers Inc. increased its stake in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. Riverview Trust Co purchased a new stake in shares of DexCom during the 1st quarter worth approximately $32,000. MV Capital Management Inc. boosted its position in shares of DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Finally, Smithfield Trust Co grew its holdings in shares of DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after purchasing an additional 165 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.